Table 5.
Characteristics | OR (95% CI) | P |
---|---|---|
Sex | ||
Male | 2·763 (0·029–5·275) | 0·663 |
Female† | ||
Age (years) | 0·976 (0·586–1·625) | 0·925 |
Migratory status | 2·452 (1·722–4·327) | 0·015 |
Migrant | ||
Local† | ||
Fever >39°C | 5·774 (2·344–14·225) | 0·000 |
Yes | ||
No† | ||
Skin or mucous membrane lesions within 48 h | 0·045 (0·015–0·130) | 0·000 |
Yes | ||
No† | ||
Type of health facility, first visit | ||
Private clinic | 2·647 (1·245–5·632) | 0·011 |
Community health centre | 1·921 (0·455–3·321) | 0·190 |
District hospital | 1·837 (0·203–6·618) | 0·588 |
City-level hospital/medical centre† | ||
Time between onset and first visit (days) | 1·514 (1·194–1·919) | 0·001 |
Time between onset and diagnosis (days) | 1·486 (1·090–2·025) | 0·012 |
Insurance status | ||
Has health insurance | 0·676 (0·434–1·055) | 0·085 |
Has no insurance† | ||
Medication within 72 h (answer of ‘no’†) | ||
(1) Self-medication | 1·313 (0·496–3·475) | 0·584 |
(2) Any antibiotics use | 0·649 (0·105–4·015) | 0·642 |
(3) Any antiviral medicine use | 0·811 (0·185–3·568) | 0·782 |
(4) Any oral antipyretics use | 1·832 (1·155–2·906) | 0·010 |
(5) Any intramuscular pyrazolone use | 3·364 (2·181–5·187) | 0·000 |
(6) Any intravenous glucocorticoid use | 2·284 (1·064–4·900) | 0·000 |
(2)+(3) | 0·979 (0·069–13·979) | 0·988 |
(2)+(4) | 1·046 (0·828–3·901) | 0·676 |
(3)+(4) | 1·006 (0·724–2·348) | 0·218 |
(2)+(3)+4) | 1·083 (0·262–4·299) | 0·208 |
(5)+(6) | 3·752 (2·324–6·059) | 0·000 |
OR, Odds ratio; CI, confidence interval.
Reference.